期刊文献+

豫西南地区结直肠癌患者EGFR、KRAS、BRAF基因突变与临床病理特征的关系 被引量:1

Relationship between gene mutation of EGFR, KRAS and BRAF and clinicopathological features of colorectal carcinoma in Southwest Henan Province
原文传递
导出
摘要 目的探讨豫西南地区结直肠癌患者表皮生长因子受体(EGFR)、Kirsten鼠肉瘤病毒癌基因(KRAS)、B-Raf原癌基因丝氨酸/苏氨酸蛋白激酶(BRAF)基因突变与临床病理特征的关系,为结直肠癌的精准医学及靶向治疗提供依据。方法选取2014年6月—2016年12月收治的结直肠癌手术切除患者268例,采用荧光定量PCR法检测EGFR基因18、19、20、21号外显子及KRAS基因12、13位密码子和BRAF基因15号外显子突变情况,比较不同临床病理特征的EGFR、KRAS、BRAF基因突变情况。结果豫西南地区结直肠癌患者EGFR、KRAS、BRAF基因突变频率分别为30%、30%、18.6%,EGFR基因突变类型为4种,以19-Del和L858R最常见,KRAS基因突变类型主要为Gly12Asp,BRAF基因突变类型主要为V600E。EGFR、KRAS基因在男性、年龄≥60岁患者中突变率均高于女性、年龄<60岁患者(均P<0.05),不同肿瘤部位、浸润深度及淋巴结转移的EGFR、KRAS、BRAF基因突变率比较,差异均无统计学意义(均P>0.05)。结论豫西南地区结直肠癌患者中,EGFR、KRAS基因突变与性别、年龄有关,BRAF基因突变与患者性别、年龄无关,EGFR、KRAS、BRAF基因突变与肿瘤部位、浸润深度及淋巴结转移均无关。 Objective To explore the relationship between gene mutation of EGFR,KRAS and BRAF and clinicopathological features of colorectal carcinoma in Southwest Henan Province,and provide basis for precision medicine and targeted therapy of colorectal cancer.Methods A total of 268 patients with colorectal cancer undergoing surgical resection from June 2014 to December 2016 were selected,the mutation of EGFR gene 18, 19, 20, 21 exon,KRAS gene 12, 13 codon and BRAF gene exon 15 were detected by fluorescence quantitative PCR, and the mutation of EGFR, KRAS and BRAF genes of different clinicopathological features was compared.Results The mutation frequencies of EGFR, KRAS and BRAF genes were 30%, 30% and 18.6% respectively. There were 4 types of EGFR gene mutations, the most common ones were 19-Del and L858 R.The mutation type of KRAS gene was mainly Gly12 Asp, and the mutation type of BRAF gene was mainly V600 E.The mutation rate of EGFR and KRAS gene in male and 60 years of age or older were significantly higher than those of females and patients aged less than 60 years(all P〈0.05).The mutation rates of EGFR, KRAS and BRAF in different tumor sites, infiltration depth and lymph node metastasis were not statistically different(all P〉0.05).Conclusions The mutations of EGFR and KRAS genes are related to sex and age in the patients with colorectal cancer in the southwest of Henan. The mutation of BRAF gene is not related to sex and age. The mutations of EGFR, KRAS and BRAF genes are not related to tumor site, infiltration depth and lymph node metastasis.
作者 李寅 LI Yin(Department of Pathology, Nanyang Medical College, Henan 473000, Chin)
出处 《社区医学杂志》 2018年第10期12-14,共3页 Journal Of Community Medicine
基金 河南省高等学校重点科研项目计划(17B310007) 南阳市科技攻关项目(2015KJGG13)
关键词 结直肠癌 表皮生长因子受体 Kirsten鼠肉瘤病毒癌基因 B-Raf原癌基因丝氨酸/苏氨酸蛋白激酶 临床病理特征 Colorectal carcinoma Epidermal growth factor receptor Kirsten rat sarcnma viral oncogene homolog B-Raf proto oncogene serinel threonine protein Kinase Clinicopathological features
  • 相关文献

参考文献5

二级参考文献53

  • 1Nordlinger B, Guiguet M, Vaillant JC,et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran~aise de Chirurgie. Cancer, 1996,77 (7) :1254- 1262. 被引量:1
  • 2Karapetis CS, Khambata-Ford S, Jonker D J, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359 ( 17 ) : 1757-1765. 被引量:1
  • 3Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic: colorectal cancer. J Clin Oncol, 2008, 26 (10) : 1626-1634. 被引量:1
  • 4Peeters M, Price TJ, Cervantes A, et al. Randomized phase IH study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010, 28(51 ) :4706-4713. 被引量:1
  • 5Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first- line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol, 2011, 22(7) :1535-1546. 被引量:1
  • 6NCCN. Clinical practice guidelines in oncology: colon cancer. Version 3. 2012 [ EB/OL]. [ 2012-07-16 ]. http://www, necn. org/professionals/physician_gls/pdf/colon, pdf. 被引量:1
  • 7Der C J, Cooper GM. Altered gene products are associated with activation of cellular Kras genes in human lung and colon carcinomas. Cell, 1983, 32( 1 ) :201-208. 被引量:1
  • 8Gideon P, John J, Frech M, et al. Mutational and kinetic: analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol, 1992,12 (5) :2050-2056. 被引量:1
  • 9Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418(6901 ) :934. 被引量:1
  • 10Samowitz WS, Curtin K, Schaffer D,et al. Relationship of K-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prey, 2000,9( 11 ) :1193-1197. 被引量:1

共引文献99

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部